BRPI0511906A - isolamento de proteìnas do plasma ou soro - Google Patents

isolamento de proteìnas do plasma ou soro

Info

Publication number
BRPI0511906A
BRPI0511906A BRPI0511906-5A BRPI0511906A BRPI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A BR PI0511906 A BRPI0511906 A BR PI0511906A
Authority
BR
Brazil
Prior art keywords
plasma
protein solution
protein
isolation
serum proteins
Prior art date
Application number
BRPI0511906-5A
Other languages
English (en)
Inventor
Allan Otto Fog Lihme
Original Assignee
Upfront Chromatography As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upfront Chromatography As filed Critical Upfront Chromatography As
Publication of BRPI0511906A publication Critical patent/BRPI0511906A/pt
Publication of BRPI0511906B1 publication Critical patent/BRPI0511906B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/206—Packing or coating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ISOLAMENTO DE PROTEìNAS DO PLASMA OU SORO. A presente invenção refere-se a um processo para o isolamento de uma ou mais proteína(s) a partir de uma solução de proteína. O processo compreendendo as etapas de: a) provisão de uma solução de proteína compreendendo uma ou mais proteína(s) específicas e tendo um pH e uma resistência ou condutividade iónica pré-ajustada, b) aplicação da solução de proteína a uma coluna de leito revestido ou leito expandido compreendendo um absorvente e c) obtenção de uma ou mais proteínas a partir da coluna; onde a solução de proteína foi suplementada com um álcool.
BRPI0511906-5A 2004-06-07 2005-06-07 Processo para o isolamento em grande escala de uma ou mais proteína(s) a partir de uma solução de proteína BRPI0511906B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400891 2004-06-07
DKPA200400891 2004-06-07
DKPA200401062 2004-07-05
DKPA200401062 2004-07-05
PCT/DK2005/000378 WO2005121163A2 (en) 2004-06-07 2005-06-07 Isolation of plasma or serum proteins

Publications (2)

Publication Number Publication Date
BRPI0511906A true BRPI0511906A (pt) 2008-01-15
BRPI0511906B1 BRPI0511906B1 (pt) 2021-11-30

Family

ID=34969001

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511906-5A BRPI0511906B1 (pt) 2004-06-07 2005-06-07 Processo para o isolamento em grande escala de uma ou mais proteína(s) a partir de uma solução de proteína

Country Status (10)

Country Link
US (3) US9624260B2 (pt)
EP (3) EP2277912B1 (pt)
CN (2) CN1972961B (pt)
AU (2) AU2005252296B2 (pt)
BR (1) BRPI0511906B1 (pt)
DK (1) DK1765866T3 (pt)
ES (2) ES2454566T3 (pt)
PL (1) PL1765866T3 (pt)
PT (1) PT1765866E (pt)
WO (1) WO2005121163A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391730T1 (de) * 2003-09-22 2008-04-15 Kamada Ltd Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
JP5010920B2 (ja) 2003-11-08 2012-08-29 プロセラ・バイオロジクス 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
MXPA06014318A (es) * 2004-06-07 2007-08-02 Avt Plasma Ltd Proceso para aislamiento de proteinas.
WO2007063129A2 (en) * 2005-12-02 2007-06-07 Novozymes A/S Insolation of peptides , polypeptides and proteins
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20120177610A1 (en) 2007-09-19 2012-07-12 Kieu Hoang Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
WO2009154695A1 (en) 2008-05-28 2009-12-23 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from blood
WO2009145722A1 (en) * 2008-05-30 2009-12-03 Ge Healthcare Bio-Sciences Ab Separation method utilizing polyallylamine ligands
RU2567811C2 (ru) * 2008-06-24 2015-11-10 Октафарма Аг Способ очистки фактора свертывания крови viii
KR101921698B1 (ko) 2008-08-21 2018-11-26 옥타파마 아게 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP5948315B2 (ja) 2010-03-30 2016-07-06 オクタファルマ・アーゲー 成長因子タンパク質の精製方法
MX2012011066A (es) 2010-03-30 2012-10-10 Octapharma Ag Proceso para purificar proteinas dependientes de vitamina k tal como el factor ix de coagulacion.
JP6088435B2 (ja) 2010-12-15 2017-03-01 バクスアルタ ゲーエムベーハー 導電率グラディエントを用いる溶出液収集
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US8802448B2 (en) 2011-07-27 2014-08-12 Pall Corporation Mixed mode ligands
TW201335181A (zh) * 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
GB201206530D0 (en) * 2012-04-13 2012-05-30 Vivacta Ltd An assay label
US20140031527A1 (en) * 2012-07-27 2014-01-30 Csl Limited Method for polishing albumin
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
CN102977180B (zh) * 2012-11-06 2016-03-16 中国科学院过程工程研究所 一种综合利用Cohn组分IV的方法
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
CN103130868B (zh) * 2013-03-12 2014-09-17 合肥天麦生物科技发展有限公司 一种蛋白质或多肽的纯化方法
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
US9663553B2 (en) * 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
US10266561B2 (en) * 2015-09-28 2019-04-23 Kieu Hoang Method for separating proteins from animal or human plasma, or plants, using a pH gradient method
CN106085992A (zh) * 2016-06-16 2016-11-09 武汉中原瑞德生物制品有限责任公司 一种提高人凝血酶原复合物中fⅶ收率的方法
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
CN110691973B (zh) 2017-04-25 2024-11-29 普罗瑟拉生物公司 用于定量间α抑制剂蛋白的方法
US11866743B1 (en) 2017-05-31 2024-01-09 Teledyne Flir Detection, Inc. Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules
JP7218344B2 (ja) * 2017-07-10 2023-02-06 武田薬品工業株式会社 液体をインキュベートおよびウイルスを不活化するための方法
CA3118156A1 (en) 2018-12-12 2020-06-18 Purilogics, LLC Affinity membrane and method of preparation
EP3917943A4 (en) * 2019-02-01 2022-12-07 Ohio State Innovation Foundation PROTEINS PURIFICATION PROCEDURES
CN110215739A (zh) * 2019-07-15 2019-09-10 大连医科大学 一种离子型亲水前处理硅胶材料的制备方法
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
CN111603802A (zh) * 2020-05-10 2020-09-01 上海灿实工程设备有限公司 一种用于血液制品的吸附罐
CN112409476B (zh) * 2020-08-13 2022-03-29 中元汇吉生物技术股份有限公司 四种血液来源蛋白的纯化方法
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
CN112827217A (zh) * 2020-12-29 2021-05-25 苏州良辰生物医药科技有限公司 一种层析柱清洗液及其应用
US20240352065A1 (en) * 2021-09-28 2024-10-24 LIHME PROTEIN SOLUTIONS ApS Improved protein sorption and filtration apparatus
CN116217710B (zh) * 2023-04-23 2025-05-27 华兰生物工程重庆有限公司 一种从血浆中提取分离IgM与凝血因子Ⅶ的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469193A (en) * 1942-02-09 1949-05-03 Research Corp Protein fractionation
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
US4156681A (en) 1974-03-28 1979-05-29 Plasmesco Ag Process for isolating albumin from blood
JPS57168157A (en) 1981-02-12 1982-10-16 Asahi Chem Ind Co Ltd High performance liquid chromatography column and analysis method using the same
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
DK165090D0 (da) 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
DK52791D0 (da) 1991-03-22 1991-03-22 Kem En Tec As Adsorptionsmatricer
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
US5502022A (en) 1994-05-16 1996-03-26 Biosepra, Inc. Chromatography adsorbents utilizing mercapto heterocyclic ligands
EP0699687B1 (en) 1994-08-31 2004-01-28 Mitsubishi Pharma Corporation Process for purifying recombinant human serum albumin
US5837826A (en) 1995-02-27 1998-11-17 Regents Of The University Of Minnesota Protein adsorption by very dense porous zirconium oxide particles in expanded beds
SE9503926D0 (sv) * 1995-11-07 1995-11-07 Pharmacia Biotech Ab Adsorptionsförfarande och separationsmedium
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
AU729039C (en) * 1996-08-30 2001-08-02 Upfront Chromatography A/S Isolation of immunoglobulins
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
US20020104801A1 (en) * 1998-04-06 2002-08-08 Nicolas Voute Small dense microporous solid support materials, their preparation,and use for purification of large macromolecules and bioparticles
DE19823814A1 (de) 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
DE69939590D1 (de) 1998-06-18 2008-10-30 Upfront Chromatography As Kope Expandiertes bett absorptionssystem
EP1131147A1 (en) 1998-10-31 2001-09-12 Amersham Pharmacia Biotech AB A new system and its units
AU3418900A (en) 1999-03-26 2000-10-16 Upfront Chromatography A/S Fluidised bed purification of bio-macromolecules such as plasmid dna, chromosomal dna, rna, viral dna, bacteria and viruses
WO2001085329A2 (en) 2000-05-12 2001-11-15 Upfront Chromatography A/S A bed adsorption system
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
EP1345666A1 (en) 2000-12-29 2003-09-24 Upfront Chromatography A/S Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids
NZ530152A (en) 2001-06-01 2005-07-29 Upfront Chromatography As Fractionation of protein containing mixtures
CN1207064C (zh) * 2002-03-29 2005-06-22 华兰生物工程股份有限公司 一种冻干人纤维蛋白胶的生产工艺
AU2003242509A1 (en) 2002-07-11 2004-02-02 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
AU2004222627B2 (en) * 2003-03-21 2009-12-03 Upfront Chromatography A/S Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
EP2522354B1 (en) * 2011-05-12 2017-08-23 CSL Behring GmbH Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins

Also Published As

Publication number Publication date
US20160009757A1 (en) 2016-01-14
EP2277912B1 (en) 2016-09-28
CN1972961A (zh) 2007-05-30
EP2277912A2 (en) 2011-01-26
US20070299251A1 (en) 2007-12-27
CN1972961B (zh) 2012-12-26
EP3127916A1 (en) 2017-02-08
AU2005252296A1 (en) 2005-12-22
US9624260B2 (en) 2017-04-18
EP1765866A2 (en) 2007-03-28
DK1765866T3 (en) 2014-03-24
EP2277912A3 (en) 2011-05-04
AU2009238344B2 (en) 2012-02-16
PT1765866E (pt) 2014-04-14
AU2005252296B2 (en) 2009-08-20
ES2454566T3 (es) 2014-04-10
US9428545B2 (en) 2016-08-30
AU2009238344A1 (en) 2009-12-10
EP1765866B1 (en) 2014-01-08
US20170282095A1 (en) 2017-10-05
PL1765866T3 (pl) 2014-06-30
WO2005121163A3 (en) 2006-03-23
ES2606078T3 (es) 2017-03-17
BRPI0511906B1 (pt) 2021-11-30
WO2005121163A2 (en) 2005-12-22
CN102924565A (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
BRPI0511906A (pt) isolamento de proteìnas do plasma ou soro
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
AU2016222301A1 (en) Isolation and purification of antibodies using Protein A affinity chromatography
BRPI0920572A8 (pt) Inativação viral durante a purificação dos anticorpos
EP2428223A3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
WO2007127198A3 (en) Protein crosslinkers, crosslinking methods and applications thereof
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
BRPI0721238B8 (pt) método de purificação da apolipoproteina a-1
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
EP1904043A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND / OR SERUM RETINOL RBP MODULATION
BRPI0710637A2 (pt) análise do perfil de expressão diferencial de fenótipos de cultura celular e seus usos
ATE538199T1 (de) Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins
BRPI0415277A (pt) célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo
BRPI0607751A8 (pt) organismo hospedeiro, sistema de cultura de célula, método para melhorar a produtividade da expressão de proteína dependente da vitamina k recombinante ou de um derivado desta funcionalmente ativo em um organismo hospedeiro, e, proteína dependente da vitamina k recombinante
WO2008054595A3 (en) Drug controlled molecular tags
WO2007008073A3 (en) METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
BRPI0509263A (pt) processo para purificar mesotriona
WO2009151337A3 (en) Novel retinoid inducible factor and uses thereof
DE602005011667D1 (de) Proteinallergenderivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: THERAPURE BIOPHARMA INC (CA)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THERAPURE BIOPHARMA INC (CA)

B25A Requested transfer of rights approved

Owner name: THERAPURE BIOPHARMA INC (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: EVOLVE BIOLOGICS INC. (CA)